1 jan 1997 ano - Rituximab
Descrição:
For use in patients with treatment-resistant, low-grade or follicular B-cell non-Hodgkin lymphoma (NHL), the Food and Drug Administration (FDA) approves rituximab, a monoclonal antibody.
Adicionado na linha do tempo:
Data: